2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosis
2020
Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis.
Haque LY, Jakab S, Deng Y, Ciarleglio MM, Tetrault JM. Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis. Journal Of Addiction Medicine 2020, 14: e337-e343. PMID: 32530887, PMCID: PMC9033633, DOI: 10.1097/adm.0000000000000677.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersAddiction treatmentAlcohol-related liver diseaseImpact of SUDHepatitis C infectionMedical record reviewMinority of patientsNumber of hospitalizationsRoutine clinical careAlcohol use disorderHepatology clinicC infectionCause mortalityConsecutive patientsMedian ageCommon etiologyLiver diseaseRecord reviewSignificant morbidityRetrospective studySUD careCirrhosisClinical careHospitalization
2019
The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortex
2016
Unhealthy Alcohol Use
Holt S, Tetrault J. Unhealthy Alcohol Use. Clinics In Liver Disease 2016, 20: 429-444. PMID: 27373607, DOI: 10.1016/j.cld.2016.02.003.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useAlcohol useSymptom-triggered approachAlcohol use disorderAlcohol withdrawalAppropriate treatmentRoutine screeningPatient motivationUse disordersBrief interventionHazardous drinkingBehavioral therapyHeavy drinkingPatientsRobust dataBehavioral changesDrinkingTwelve-step programsMedicationsTherapyBenzodiazepinesAbstinenceHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infectionEffect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings. Alcohol Clinical And Experimental Research 2016, 40: 1567-1576. PMID: 27246567, PMCID: PMC4930423, DOI: 10.1111/acer.13110.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholic IntoxicationAlcohol-Related DisordersAssociation LearningBlood PressureCravingDose-Response Relationship, DrugDouble-Blind MethodEthanolExecutive FunctionFemaleHeart RateHumansMaleMemory, Short-TermNicotinic AgonistsPsychological TestsPsychomotor PerformanceVareniclineYoung AdultConceptsPerceptual-motor functionAlcohol use disorderExecutive cognitive functionCognitive functionDose of alcoholSubjective reactivitySubjective intoxicationHigh-dose alcoholNonalcoholic control beverageAlcohol-motivated behaviorsUse disordersEffects of vareniclineAssociative learningAversive eventsLaboratory paradigmDiastolic blood pressureAlcohol cravingControl beverageMotor responsePhysiologic reactivityAlcohol-related increasesLaboratory sessionsMotor functionBlood pressurePreliminary investigationEffect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. Journal Of Addiction Medicine 2016, 10: 166-173. PMID: 27159341, PMCID: PMC4880525, DOI: 10.1097/adm.0000000000000208.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol consumptionUse disordersVarenicline doseD dosePlasma levelsDose of vareniclineDoses of vareniclineFrequency of insomniaPlacebo-controlled investigationHigher plasma levelsDose of alcoholAlcohol Self-AdministrationSelf-administration periodMedication pretreatmentAdverse eventsEdition criteriaVareniclineLow doseSide effectsAlcohol cravingMeeting criteriaPhysiologic responsesAlcohol-related outcomes
2009
Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E. Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. Biological Psychiatry 2009, 66: 185-190. PMID: 19249750, PMCID: PMC2863311, DOI: 10.1016/j.biopsych.2009.01.029.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersSelf-administration periodAlcohol consumptionPartial nicotinic agonistPlacebo-controlled investigationEffects of vareniclineReduced ethanol intakeAlcohol Self-AdministrationAlcohol use disorderNicotinic acetylcholine receptorsMedication pretreatmentAdverse eventsNumber of drinksPreclinical evidenceAdditional drinkEthanol intakeTobacco dependenceDaily smokersPriming doseVareniclineComorbid disordersNicotinic agonistsUse disordersPriming drinkPotential treatment